Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
J Sex Med ; 19(4): 594-602, 2022 04.
Article in English | MEDLINE | ID: mdl-35184995

ABSTRACT

BACKGROUND: Prostate artery embolization (PAE) is an emerging therapy for lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). AIM: This retrospective study was conducted to assess the effect of prostate artery embolization (PAE) on erectile function in a cohort of patients with LUTS attributable to BPH at 3-months after the procedure. METHODS: A retrospective review was performed on 167 patients who underwent PAE. Data collected included Sexual Health Inventory in Men (SHIM) scores at 3, 6, and 12 months post-PAE, in conjunction with the International Prostate Symptom Scores (IPSS), Quality of Life (QoL) scores, and prostate volumes. Primary outcome was erectile function as assessed by SHIM scores at 3 months after PAE. An analysis was performed to identify patients with a ±5-point SHIM change to group them according to this minimum clinically significant difference in erectile function. Adverse events were recorded using the Clavien-Dindo (CD) classification. OUTCOMES: At 3 months following PAE, median IPSS decreased by 16.0 [IQR, 9.0-22.0] points, median QOL decreased by 4.0 [IQR, 2.0-5.0] points, and median prostate volume decreased by 33 g [IQR, 14-55]. RESULTS: Median SHIM score was 17.0 [IQR, 12.0-22.0] at baseline, 18.0 [IQR, 14.0-23.0] at 3 months [P = .031], 19.0 [IQR, 14.5-21.5] at 6 months [P = .106] and 20 [IQR, 16.0-24.0] at 12 months [P = .010] following PAE. In patients with no erectile dysfunction (ED) at baseline, 21% (n = 9) reported some degree of decline in erectile function post-PAE. However, 38% (n = 40) of patients who presented with mild-to-moderate ED reported improvement in their erectile function 3 months following PAE. Overall, the changes in baseline SHIM score were relatively small; 82% (n = 137) of patients did not have more than 5 points of change in their SHIM scores at 3 months following PAE. CLINICAL IMPLICATIONS: Our findings suggest PAE has no adverse impact on erectile function for most patients. STRENGTHS & LIMITATIONS: The study was performed at a single center with 1 operator's experience, and is retrospective with no control group. CONCLUSION: Findings suggest that prostate artery embolization has no adverse effect on erectile function in the majority of patients with LUTS attributable to BPH at 3 months after the procedure. Bhatia S, Acharya V, Jalaeian H, et al., Effect of Prostate Artery Embolization on Erectile Function - A Single Center Experience of 167 Patients. J Sex Med 2022;19:594-602.


Subject(s)
Erectile Dysfunction , Lower Urinary Tract Symptoms , Prostatic Hyperplasia , Arteries , Erectile Dysfunction/complications , Erectile Dysfunction/therapy , Humans , Lower Urinary Tract Symptoms/complications , Lower Urinary Tract Symptoms/therapy , Male , Prostate , Prostatic Hyperplasia/complications , Prostatic Hyperplasia/therapy , Quality of Life , Retrospective Studies , Treatment Outcome
2.
Knee ; 41: 38-47, 2023 Mar.
Article in English | MEDLINE | ID: mdl-36608360

ABSTRACT

BACKGROUND: Genicular artery embolization (GAE) is a novel technique and has the potential to provide midterm relief of pain for patients with mild-to-moderate knee osteoarthritis resistant to conservative management. This study compares the efficacy and safety of trisacryl gelatin microspheres to Imipenem/Cilastatin particles for GAE with 2 years of clinical follow-up. METHODS: In this retrospective study, eight patients with knee osteoarthritis (11 knees) who underwent GAE with 100-300 µm trisacryl gelatin microspheres particles were compared with six patients (nine knees) who underwent GAE with Imipenem/Cilastatin particles. Clinical outcomes were evaluated at 3-month and 24-month follow-ups and compared to baseline using the WOMAC questionnaire. RESULTS: The median follow-up was 796 days (range: 736-808). There were no significant differences in clinical outcome measures at the 3-month or 24-month follow-up. Both embolic materials resulted in a decrease in Pain WOMAC and Total WOMAC scores at 3 months (p < 0.05), and the effect of treatment on Pain WOMAC and Total WOMAC score reduction was sustained until the 24-month follow-up (p < 0.05). Minor events (Clavien-Dindo classification grade I) included transient cutaneous color change (n = 3) and transient leg numbness (n = 1) after embolization with trisacryl gelatin microspheres particles (p = 0.08). All minor adverse events resolved spontaneously. There were no major adverse events. CONCLUSION: One hundred to three hundred µm trisacryl gelatin microspheres particles can be considered for genicular artery embolization and is comparable to Imipenem/Cilastatin particles in pain reduction of moderate to severe knee osteoarthritis. A sustained effect is observed for up to 2 years of follow-up.


Subject(s)
Osteoarthritis, Knee , Humans , Osteoarthritis, Knee/drug therapy , Cilastatin, Imipenem Drug Combination , Microspheres , Retrospective Studies , Treatment Outcome , Pain/drug therapy , Pain/etiology , Arteries
3.
Turk J Urol ; 48(3): 201-208, 2022 May.
Article in English | MEDLINE | ID: mdl-35634938

ABSTRACT

OBJECTIVE: The primary purpose was to compare the completeness of adenomectomy and zonal anatomy of prostate on magnetic resonance imaging prostate after transurethral resection of prostate and Holmium enucleation of prostate. The secondary purpose was to investigate the relationship between preoperative total prostate volume and postoperative transition zone and peripheral zone volume after both procedures. MATERIAL AND METHODS: A retrospective review of all patients who underwent transurethral resection of pros- tate or Holmium enucleation of prostate over 3 years (2017-2020) and had at least 1 postoperative magnetic resonance imaging prostate was performed. Volume estimations of the prostate and individual zones were per- formed, and statistical comparisons were made to evaluate morphometric changes between the 2 procedures. RESULTS: A total of 9 patients (mean age, 71.8 years) underwent transurethral resection of prostate and 12 patients (mean age, 66.9 years) underwent Holmium enucleation of prostate. The median pre-operative prostate volume in the Holmium enucleation of prostate group was higher than the transurethral resection of prostate group (101.5 g vs. 62 g; P =.102). However, there was a significant difference in the resected tissue weight favoring Holmium enucleation of prostate over transurethral resection of prostate (P value=.004). The postoperative transition zone and peripheral zone volume as calculated by magnetic resonance imaging remained relatively constant in both procedures. The peripheral zone volume on postoperative magnetic res- onance imaging was found to be independent of transition zone volume even for very large-sized prostates. CONCLUSION: A well-performed transurethral resection of prostate or Holmium enucleation of prostate cannearly completely eliminate the transition zone volume, irrespective of the size of the prostate as confirmed by magnetic resonance imaging prostate. Additionally, the peripheral zone volume is consistent across the entire spectrum of the prostate size.

4.
Tech Vasc Interv Radiol ; 23(3): 100689, 2020 Sep.
Article in English | MEDLINE | ID: mdl-33308529

ABSTRACT

Identification of the prostatic arteries (PAs) is one of the most challenging aspects of prostate artery embolization for treatment of benign prostatic hyperplasia-associated lower urinary tract symptoms. Operators require a detailed understanding of the prostate arterial anatomy to ensure technical and clinical success with minimal complications. Due to substantial variability in internal iliac artery branch patterns and specifically the origin of the PA, we focus on 3 clinically relevant classification systems used to categorize the pelvic vasculature. These include classification systems to understand the internal iliac artery branching pattern, PA origin variation, and intraprostatic branching.


Subject(s)
Embolization, Therapeutic , Iliac Artery , Lower Urinary Tract Symptoms/therapy , Prostate/blood supply , Prostatic Hyperplasia/therapy , Radiography, Interventional , Humans , Iliac Artery/diagnostic imaging , Lower Urinary Tract Symptoms/diagnostic imaging , Lower Urinary Tract Symptoms/physiopathology , Male , Prostatic Hyperplasia/diagnostic imaging , Prostatic Hyperplasia/physiopathology
5.
Tech Vasc Interv Radiol ; 23(3): 100692, 2020 Sep.
Article in English | MEDLINE | ID: mdl-33308533

ABSTRACT

As prostate artery embolization (PAE) for treatment of lower urinary tract symptoms attributed to benign prostatic hyperplasia becomes more commonly performed, operator knowledge of the adverse events is essential to inform patient selection, patient preparation, and postprocedural management. The aim of this article is to discuss the incidence, presentation, and management of adverse effects after PAE.


Subject(s)
Embolization, Therapeutic/adverse effects , Lower Urinary Tract Symptoms/therapy , Prostate/blood supply , Prostatic Hyperplasia/therapy , Radiography, Interventional/adverse effects , Humans , Lower Urinary Tract Symptoms/diagnostic imaging , Lower Urinary Tract Symptoms/physiopathology , Male , Prostatic Hyperplasia/diagnostic imaging , Prostatic Hyperplasia/physiopathology , Risk Factors , Treatment Outcome
6.
Tech Vasc Interv Radiol ; 23(3): 100693, 2020 Sep.
Article in English | MEDLINE | ID: mdl-33308525

ABSTRACT

Many interventions to treat men with benign prostatic hyperplasia (BPH) associated lower urinary tract symptoms (LUTS) are associated with sexual side effects or complications, such as hematospermia, erectile dysfunction, or ejaculatory dysfunction. As loss of sexual function can significantly impact quality of life, an optimal treatment for BPH associated LUTS would be one without any sexual dysfunction side effects. Prostatic artery embolization is a minimally invasive treatment for men with BPH associated LUTS. The aim of this paper is to review the effects of prostatic artery embolization on sexual function and compare the sexual side effect profile to the other available BPH procedures.


Subject(s)
Embolization, Therapeutic/adverse effects , Lower Urinary Tract Symptoms/therapy , Prostate/blood supply , Prostatic Hyperplasia/therapy , Radiography, Interventional/adverse effects , Sexual Dysfunction, Physiological/etiology , Sexual Dysfunctions, Psychological/etiology , Urologic Surgical Procedures, Male/adverse effects , Humans , Lower Urinary Tract Symptoms/diagnostic imaging , Lower Urinary Tract Symptoms/physiopathology , Male , Prostatic Hyperplasia/diagnostic imaging , Prostatic Hyperplasia/physiopathology , Risk Assessment , Risk Factors , Sexual Dysfunction, Physiological/diagnosis , Sexual Dysfunction, Physiological/physiopathology , Sexual Dysfunctions, Psychological/diagnosis , Sexual Dysfunctions, Psychological/psychology , Treatment Outcome
7.
Tech Vasc Interv Radiol ; 23(3): 100694, 2020 Sep.
Article in English | MEDLINE | ID: mdl-33308527

ABSTRACT

Hematuria of prostatic origin has multiple etiologies including benign prostatic hyperplasia (BPH), iatrogenic urological trauma, prostate cancer, and radiation therapy. Hematuria secondary to benign prostatic hyperplasia can occur because of the increased vascularity of the primary gland, itself, or because of the vascular re-growth following a transurethral resection of the prostate. Prostatic hematuria usually resolves with conservative measures; however, refractory hematuria of prostatic origin may require hospitalization with treatment with blood transfusions, repeated indwelling urinary catheterization, and continuous bladder irrigation. Prostate artery embolization is an emerging minimally invasive procedural therapy for men with BPH that was originally utilized for the treatment of refractory hematuria of prostatic origin . This article aims to summarize the currently available evidence around prostate artery embolization for the treatment of refractory hematuria of prostatic origin.


Subject(s)
Embolization, Therapeutic , Hematuria/therapy , Prostatic Hyperplasia/therapy , Radiography, Interventional , Embolization, Therapeutic/adverse effects , Hematuria/diagnostic imaging , Hematuria/etiology , Hematuria/physiopathology , Humans , Male , Prostatic Hyperplasia/complications , Prostatic Hyperplasia/diagnostic imaging , Prostatic Hyperplasia/physiopathology , Radiography, Interventional/adverse effects , Risk Factors , Treatment Outcome
8.
Tech Vasc Interv Radiol ; 23(3): 100690, 2020 Sep.
Article in English | MEDLINE | ID: mdl-33308535

ABSTRACT

Prostate artery embolization (PAE) is a minimally invasive treatment for benign prostatic hyperplasia associated lower urinary tract symptoms. The prostatic arterial anatomy, origins and collaterals, are highly variable and can lead to technical pitfalls and suboptimal results during PAE. In this paper we aim to discuss the variant prostate artery origins and collateral circulation to provide a primer on relevant anatomy for interventional radiologists performing PAE.


Subject(s)
Collateral Circulation , Embolization, Therapeutic , Iliac Artery/abnormalities , Lower Urinary Tract Symptoms/therapy , Prostate/blood supply , Prostatic Hyperplasia/therapy , Radiography, Interventional , Humans , Iliac Artery/diagnostic imaging , Iliac Artery/physiopathology , Lower Urinary Tract Symptoms/diagnostic imaging , Lower Urinary Tract Symptoms/physiopathology , Male , Prostatic Hyperplasia/diagnostic imaging , Prostatic Hyperplasia/physiopathology , Regional Blood Flow
SELECTION OF CITATIONS
SEARCH DETAIL